Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autozone Inc (AZO) vs Mesoblast Limited (MESO) Price & Performance

Autozone IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Autozone Inc vs Mesoblast Limited — how do they compare? Autozone Inc trades at $3,042 (market cap $50.09B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Autozone Inc is far larger — about 23.2× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.

AZOMESO
Market Cap
$50.09B$2.16B
Sector
Consumer CyclicalTechnology
52-Week High
$4.35K$20.96
52-Week Low
$2.92K$12.88
Enterprise Value
$62.46B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autozone Inc

AutoZone (AZO) trades at $3,127.29, up 1.88% recently, with a bullish technical signal and strong analyst support. Revenue grew to $18.94B in 2025, though net income margin dipped to 13.19%. The company maintains robust cash flow from operations and recently authorized a $1.5B stock buyback, signaling confidence. Key resistance lies near $3,160, with support at $3,063.

Outlook remains positive with 73% analyst buy ratings and a $3,730 consensus price target, implying ~19% upside. Risks include margin pressure from rising costs and competitive threats. Earnings beats in recent quarters support growth, but investors should monitor execution on international expansion and capex efficiency.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Autozone Inc

AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.

Read more on AZO

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO